Layilin and platelet-driven clotting and inflammation
The Role of Layilin as a Novel Regulator of Platelet Activation and Thromboinflammation
Researchers are exploring whether the protein layilin makes platelets more likely to cause dangerous blood clots and inflammation in people with inflammatory bowel disease and related vascular risk.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Utah State Higher Education System--University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-11326243 on NIH RePORTER |
What this research studies
You'll hear how scientists study whether layilin changes how platelets behave by looking at patient blood samples, running detailed lab tests on platelets, and using disease models that mimic inflammation and clotting. They will examine platelet gene activity and protein signals to see how layilin influences platelet activation and interactions with immune cells. The team will compare samples from people with active and inactive inflammatory bowel disease to understand links between disease activity and clotting risk. Results are meant to point toward new ways to lower clotting and inflammation related to IBD.
Who could benefit from this research
Good fit: Ideal candidates would be adults with inflammatory bowel disease (Crohn's disease or ulcerative colitis), especially those with active disease or a history of thrombosis.
Not a fit: People without IBD or without platelet-driven clotting risk are unlikely to receive direct benefit from this project.
Why it matters
Potential benefit: If successful, this work could identify a new target (layilin) to reduce harmful clotting and inflammation in people with IBD and related thrombotic risk.
How similar studies have performed: Platelet-driven inflammation is a known contributor to clotting risk, but targeting layilin is a novel approach with limited prior human evidence.
Where this research is happening
Salt Lake City, United States
- Utah State Higher Education System--University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Petrey, Aaron Christopher — Utah State Higher Education System--University of Utah
- Study coordinator: Petrey, Aaron Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.